File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Prophylactic effect of somatostatin on post-ERCP pancreatitis: A randomized controlled trial

TitleProphylactic effect of somatostatin on post-ERCP pancreatitis: A randomized controlled trial
Authors
Issue Date1999
PublisherMosby, Inc. The Journal's web site is located at http://www.elsevier.com/locate/gie
Citation
Gastrointestinal Endoscopy, 1999, v. 49 n. 5, p. 593-598 How to Cite?
AbstractBackground: Somatostatin is a potent inhibitor of pancreatic secretion and has been studied for its prophylactic effect on post-ERCP pancreatitis. However, results of previous trials have been inconclusive. Methods: A prospective double-blind controlled study was performed to evaluate the effectiveness of somatostatin in preventing post-ERCP pancreatitis. Post- ERCP enzyme elevation, abdominal pain and pancreatitis were evaluated and compared between 109 patients randomized to receive somatostatin infusion and 111 patients randomized to receive normal saline infusion (placebo); both started 30 minutes before ERCP and continued for 12 hours. Results: Post- ERCP elevation of serum amylase and lipase levels at 6 and 24 hours after ERCP was less frequent in the group given somatostatin but not statistically significant. There was a tendency toward lower mean serum amylase and lipase levels at 24 hours in patients given somatostatin, although the difference was not statistically significant either. Eight patients given somatostatin (7%) and 18 patients given placebo (16%) had significant abdominal pain after ERCP requiring analgesia (p = 0.04). The frequency of clinical pancreatitis was significantly lower in patients given somatostatin (3%) than in those given placebo (10%) (p = 0.03). Conclusions: Prophylactic treatment with somatostatin reduced the frequency of post-ERCP pancreatitis.
Persistent Identifierhttp://hdl.handle.net/10722/83950
ISSN
2015 Impact Factor: 6.217
2015 SCImago Journal Rankings: 2.390
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorPoon, RTPen_HK
dc.contributor.authorYeung, Cen_HK
dc.contributor.authorLo, CMen_HK
dc.contributor.authorYuen, WKen_HK
dc.contributor.authorLiu, CLen_HK
dc.contributor.authorFan, STen_HK
dc.date.accessioned2010-09-06T08:47:09Z-
dc.date.available2010-09-06T08:47:09Z-
dc.date.issued1999en_HK
dc.identifier.citationGastrointestinal Endoscopy, 1999, v. 49 n. 5, p. 593-598en_HK
dc.identifier.issn0016-5107en_HK
dc.identifier.urihttp://hdl.handle.net/10722/83950-
dc.description.abstractBackground: Somatostatin is a potent inhibitor of pancreatic secretion and has been studied for its prophylactic effect on post-ERCP pancreatitis. However, results of previous trials have been inconclusive. Methods: A prospective double-blind controlled study was performed to evaluate the effectiveness of somatostatin in preventing post-ERCP pancreatitis. Post- ERCP enzyme elevation, abdominal pain and pancreatitis were evaluated and compared between 109 patients randomized to receive somatostatin infusion and 111 patients randomized to receive normal saline infusion (placebo); both started 30 minutes before ERCP and continued for 12 hours. Results: Post- ERCP elevation of serum amylase and lipase levels at 6 and 24 hours after ERCP was less frequent in the group given somatostatin but not statistically significant. There was a tendency toward lower mean serum amylase and lipase levels at 24 hours in patients given somatostatin, although the difference was not statistically significant either. Eight patients given somatostatin (7%) and 18 patients given placebo (16%) had significant abdominal pain after ERCP requiring analgesia (p = 0.04). The frequency of clinical pancreatitis was significantly lower in patients given somatostatin (3%) than in those given placebo (10%) (p = 0.03). Conclusions: Prophylactic treatment with somatostatin reduced the frequency of post-ERCP pancreatitis.en_HK
dc.languageengen_HK
dc.publisherMosby, Inc. The Journal's web site is located at http://www.elsevier.com/locate/gieen_HK
dc.relation.ispartofGastrointestinal Endoscopyen_HK
dc.rightsGastrointestinal Endoscopy. Copyright © Mosby, Inc.en_HK
dc.titleProphylactic effect of somatostatin on post-ERCP pancreatitis: A randomized controlled trialen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0016-5107&volume=49&spage=593&epage=598&date=1999&atitle=Prophylactic+effect+of+somatostatin+on+post-ERCP+pancreatitis:+a+randomized+controlled+trialen_HK
dc.identifier.emailPoon, RTP: poontp@hkucc.hku.hken_HK
dc.identifier.emailLo, CM: chungmlo@hkucc.hku.hken_HK
dc.identifier.emailFan, ST: stfan@hku.hken_HK
dc.identifier.authorityPoon, RTP=rp00446en_HK
dc.identifier.authorityLo, CM=rp00412en_HK
dc.identifier.authorityFan, ST=rp00355en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/S0016-5107(99)70387-1en_HK
dc.identifier.pmid10228257-
dc.identifier.scopuseid_2-s2.0-0032962285en_HK
dc.identifier.hkuros40710en_HK
dc.identifier.volume49en_HK
dc.identifier.issue5en_HK
dc.identifier.spage593en_HK
dc.identifier.epage598en_HK
dc.identifier.isiWOS:000080231100008-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridPoon, RTP=7103097223en_HK
dc.identifier.scopusauthoridYeung, C=25950985200en_HK
dc.identifier.scopusauthoridLo, CM=7401771672en_HK
dc.identifier.scopusauthoridYuen, WK=7102761292en_HK
dc.identifier.scopusauthoridLiu, CL=7409789712en_HK
dc.identifier.scopusauthoridFan, ST=7402678224en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats